Author(s): Josephine Pudhumai Selvi1, Sivanupandian Sivasubramanian2, Karthik Manohar3
The world’s most common cancer and the second main cause of cancer death among women in the United States is breast cancer. Breast cancer is the second most common cancer among women in India after carcinoma cervix. A single parameter with the strongest prognostic significance is hormone receptor status. Intracellular steroid-hormone receptor proteins, primarily Oestrogen Receptor (ER) and Progesterone Receptor (PR) have received intensive study both as indicator of prognosis and as guide to hormone therapy. Recently, importance of HER2/neu in breast cancer has been a topic of considerable interest, both in its role as a prognostic indicator and as a predictor of response to therapy.
The aim of the study is to assess the incidence of hormone receptor positivity in females with carcinoma breast and to compare hormonal receptor status with clinicopathological grading of the tumour.
MATERIALS AND METHODS
A study of cases of carcinoma breast in females were done. Sample included 75 patients. Patients for clinical study were selected from the general surgical wards of Tirunelveli Medical College Hospital for a period of 18 months.
Out of 75 patients, 52 patients (69.33%) were positive for oestrogen receptor and 23 (30.66%) were negative. 39 patients (52%) were progesterone receptor positive and 36 (48%) were progesterone receptor negative. 28 (37.33%) patients had Her2 receptor positive and 47 (62.66%) were negative.
These results were comparable with the previous studies and thus reinforce the usefulness of estimation of the receptor status for treatment purpose in breast carcinoma.